Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Cai, 2002, Comparison of efficacy and toxicity between gemcitabine plus carboplatin and gemcitabine plus cisplatin in the treatment of advanced non-small cell lung cancer, Zhongguo Fei Ai Za Zhi, 5, 427
Chen, 2006, A phase II randomized study of paclitaxel plus carboplatin or cisplatin against chemo-naive inoperable non-small cell lung cancer in the elderly, Journal of Thoracic Oncology, 1, 141, 10.1016/S1556-0864(15)31529-X
Ferry, 2011, British Thoracic Oncology Group Trial, BTOG2: Randomised phase III clinical trial of gemcitabine (1250mg/m2) combined with cisplatin 50 mg/m2 (GC50) versus cisplatin 80 mg/m2 (GC80) versus carboplatin AUC 6 (GCb6) in advanced NSCLC, Thorax, 66, A41, 10.1136/thoraxjnl-2011-201054b.85
Fossella, 2003, Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group, Journal of Clinical Oncology, 21, 3016, 10.1200/JCO.2003.12.046
Mazzanti, 2003, Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer, Lung Cancer, 41, 81, 10.1016/S0169-5002(03)00140-5
Rosell, 2002, Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial, Annals of Oncology, 13, 1539, 10.1093/annonc/mdf332
Schiller, 2002, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer, New England Journal of Medicine, 346, 92, 10.1056/NEJMoa011954
Sweeney, 2001, Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma, Cancer, 92, 2639, 10.1002/1097-0142(20011115)92:10<2639::AID-CNCR1617>3.0.CO;2-8
Yan, 2001, A randomized phase II trial of paclitaxel in combination chemotherapy with platinum in the treatment of non-small cell lung cancer, Zhongguo Fei Ai Za Zhi, 4, 188
Zatloukal, 2003, Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial, Lung Cancer, 41, 321, 10.1016/S0169-5002(03)00233-2
Belani, 2001, Phase III randomized trial of docetaxel in combination with cisplatin or carboplatin or vinorelbine plus cisplatin in advanced non-small cell lung cancer: interim analysis, Seminars in Oncology, 28, 10, 10.1016/S0093-7754(01)90201-5
Belani, 2002, Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer, Seminars in Oncology, 29, 4, 10.1016/S0093-7754(02)90001-1
Belani, 2006, Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial, Lung Cancer, 53, 231, 10.1016/j.lungcan.2006.05.003
Fossella, 2001, Docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCb) versus vinorelbine + cisplatin (VC) in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer (NSCLC): results of a multicenter, randomized phase III study, European Journal of Cancer, 37, S154, 10.1016/S0959-8049(01)81054-6
Gatzemeier, 1999, Randomized pan-European trial comparing paclitaxel (TAX)/carboplatin (CAR) versus paclitaxel/cisplatin (CIS) in advanced non-small cell lung cancer (NSCLC), European Journal of Cancer, 35, S246, 10.1016/S0959-8049(99)81393-8
Macha HN Gatzemeier U Betticher DC Keppler U Berthet P Chemaissan A Randomized multicenter trial comparing paclitaxel (TAX)/carboplatin (CAR) versus paclitaxel/cisplatin (CIS) in advanced non-small cell lung cancer (NSCLC): results of a planned interim analysis Proceedings of the American Society of Clinical Oncology Los Angeles 1998 465a (abstract 1789)
Mazzanti P Lippe P Battelli N Mattioli R Buzzi F Trivisonne R Gemcitabine-cisplatin (GP) vs gemcitabine-carboplatin (GC) in advanced non-small cell lung cancer (ANSCLC): a multicenter phase II randomized trial of a 21-day schedule. Preliminary results Proceedings of the American Society of Clinical Oncology New Orleans American Society of Clinical Oncology 2000 540a (abstract 2125)
Mazzanti P Massacesi C Mattioli R Trivisonne R Buzzi F De Signoribus G Gemcitabine-cisplatin (GP) vs gemcitabine-carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): a multicenter phase II randomized trial European Journal of Cancer Lisbon European Journal of Cancer 2001 S50
Novakova L Petruzelka L Zemanova M Kolek V Grygarkova I Sixtova D Gemcitabine plus cisplatin (GCis) versus gemcitabine plus carboplatin (GCarb) in patients with stage IIIB and IV non-small lung cancer (NSCLC): final results of Czech Lung Cancer Co-operative Group phase III randomized trial Proceedings of the American Society of Clinical Oncology 2002 abstract 1225
Ramlau, 2007, Results of Polish medical centres within an international randomized phase III study of docetaxel plus cisplatin and docetaxel plus carboplatin versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer, Journal of Oncology, 57, 146
Rodriguez J Pawel J Pluzanska A Gorbounova V Fossella F Kaukel E A multicenter, randomized phase III study of docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCB) vs. vinorelbine + cisplatin (VC) in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer Proceedings of the American Society of Clinical Oncology 2001 314a
American Cancer Society Cancer facts & figures 2010 www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-and-figures-2010
Ardizzoni, 2007, Cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis, Journal of the National Cancer Institute, 99, 847, 10.1093/jnci/djk196
Azzoli, 2009, American Society of Clinical Oncology clinical practice guideline: update on chemotherapy for stage IV non-small-cell lung cancer, Journal of Clinical Oncology, 27, 6251, 10.1200/JCO.2009.23.5622
Baggstrom, 2007, Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis, Journal of Thoracic Oncology, 2, 845, 10.1097/JTO.0b013e31814617a2
Hopewell, 2007, Grey literature in meta-analyses of randomized trials of health care interventions, Cochrane Database of Systematic Reviews, 10.1002/14651858.MR000010.pub3
Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), European Journal of Cancer, 45, 228, 10.1016/j.ejca.2008.10.026
Govindan, 2006, Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database, Journal of Clinical Oncology, 24, 4539, 10.1200/JCO.2005.04.4859
Green, 2003, Clinical Trials in Oncology
Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated September 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org
Hotta, 2004, Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer, Journal of Clinical Oncology, 22, 3852, 10.1200/JCO.2004.02.109
Jiang, 2007, A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer, Lung Cancer, 57, 348, 10.1016/j.lungcan.2007.03.014
National Cancer Institute Common toxicity criteria ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf
NSCLC Collaborative Group, 1995, Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials, BMJ, 311, 899, 10.1136/bmj.311.7010.899
Paccagnella, 2004, Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial, Lung Cancer, 43, 83, 10.1016/S0169-5002(03)00280-0
Parmar, 1998, Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints, Statistics in Medicine, 17, 2815, 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
Pocock, 1975, Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial, Biometrics, 31, 103, 10.2307/2529712
Reck, 2010, Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL), Annals of Oncology, 21, 1804, 10.1093/annonc/mdq020
Reed, 2005, Pharmacology of cancer chemotherapy, Cancer: Principles and Practice of Oncology, 419
The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 2011
Sandler, 2006, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer, New England Journal of Medicine, 355, 2542, 10.1056/NEJMoa061884
Scagliotti, 2008, Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer, Journal of Clinical Oncology, 26, 3543, 10.1200/JCO.2007.15.0375
Sobin, 2002, Union for International Cancer Control (UICC), TNM Classification of Malignant Tumours, 1